moneyheap
XBI · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is State Street SPDR S&P Biotech ETF (XBI) stock moving?
No news items were published about XBI in the 14 days before Nov 10, and no SEC filings were made in the prior 45 days, so this view rests only on price and volume. XBI closed at $151.64 on Oct 22 and rose to a $159.10 close on Nov 4, with an intraday high of $160.29 on Oct 29. It then fell to a $148.40 close on Nov 5, on the heaviest volume in the window at 13.76M shares. The price recovered over the next three sessions to $155.06 on Nov 10, about 4.5% above the Nov 5 close but roughly 3% below the Nov 4 close. Volume eased to 7.0M shares on Nov 10, and the close sits near the session VWAP of $155.08. The data shows no identifiable sector catalyst, so the direction of the next week depends on whether the rebound holds above the Nov 5 area without a new driver.
About State Street SPDR S&P Biotech ETF
XBI is a State Street SPDR ETF, launched in 2006, that holds about 160 US biotechnology stocks from the S&P Biotechnology Select Industry Index. Unlike most biotech funds, which are dominated by a few giants, it weights its holdings roughly equally, so most of its exposure is to small and mid-sized drug developers. No single stock is more than about 2% of the fund.
How the fund works
The fund passively tracks the S&P Biotechnology Select Industry Index. It uses a modified equal-weight method and rebalances every quarter, so a big name like AbbVie or Biogen ends up with about the same weight as a small clinical-stage company. The yearly fee (expense ratio) is about 0.35%, and the fund held roughly $10–11B in assets in late 2026. It pays only a tiny dividend, around 0.35% a year. The main risk is volatility: many holdings have no profits yet and can swing sharply on trial results or funding news.
What usually moves XBI
- Clinical trial results and FDA decisions
- Interest rates and access to funding
- Biotech mergers and acquisitions
- Drug pricing policy and regulation
- Overall appetite for small-cap risk